NCT05844618View on ClinicalTrials.gov

Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

November 7, 2024

Study Completion Date

March 24, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

Triamcinolone Acetonide (Aristocort® C)

On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.

DRUG

Vehicle

On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.

Trial Locations (1)

H2X 2V1

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Innovaderm Research Inc.

OTHER